Doxorubicin-fucoidan-gold nanoparticles composite for dualchemo-photothermal treatment on eye tumors
Metrics: PDF 1552 views | HTML 3631 views | ?
Hyejin Kim1,*, Van Phuc Nguyen1,*, Panchanathan Manivasagan2,*, Min Jung Jung3, Sung Won Kim4, Junghwan Oh1,2 and Hyun Wook Kang1,2
1Interdisciplinary Program of Biomedical Mechanical and Electrical Engineering, Pukyong National University, Busan, South Korea
2Department of Biomedical Engineering and Center for Marine-Integrated Biomedical Technology (BK 21 Plus), Pukyong National University, Busan, South Korea
3Department of Pathology, Kosin University College of Medicine, Busan, South Korea
4Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, Busan, South Korea
*These authors contributed equally to this work
Sung Won Kim, email: [email protected]
Junghwan Oh, email: [email protected]
Hyun Wook Kang, email: [email protected]
Keywords: doxorubicin; gold-nanoparticles; photothermal therapy; chemotherapy; eye tumor
Received: October 16, 2017 Accepted: December 01, 2017 Published: December 09, 2017
The current research demonstrates the feasible biomedical application of AuNPs coated with doxorubicin (Dox)-loaded fucoidan (Fu) for dual-chemotherapy and photothermal treatment (PTT) on eye tumors in vitro and in vivo. Marine-derived Fu was used as a capping agent to achieve high photostability for AuNPs, and Dox as a FDA-approved anti-cancer drug was added to induce chemotherapy. The synthesized Dox-Fu@AuNPs exhibited high cytotoxicity on the tumor cells and strong light absorption for temperature increase in vitro. After intratumoral injection of Dox-Fu@AuNPs in the rabbit eye tumors, PTT-assisted Dox-Fu@AuNPs entailed the complete removal of the eye tumors without recurrence for 14 days after the treatment. Photoacoustic image contrast from the tumor regions was enhanced due to selective light absorption by the administered Dox-Fu@AuNPs. Therefore, the proposed Dox-Fu@AuNPs can be a potential nano-theranostic material for treating and diagnosing the eye tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.